Cencora, Inc.
COR Healthcare Medical Distribution
Cencora, Inc.’s revenue for fiscal 2025 (year ended September 2025) was $321.3 billion, up 9.31% from fiscal 2024. In the quarter to June 2026, revenue grew 5.07%, EPS grew 11.3%, free cash flow grew 3,385.3% and total debt rose 42.3%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for three consecutive years, revenue growth for ten; insiders bought in the last twelve months.
Follow COR
Cencora, Inc. (COR) Net income
Cencora, Inc.'s net income for fiscal 2025 was $1.6B, unchanged from fiscal 2024. Over the twelve months to 30 June 2026 it was $2.6B. Over the past ten years it has ranged from −$3.4B (fiscal 2020) to $1.7B (fiscal 2023); the current reading is higher than 73% of that period. Cencora, Inc. ranks 2nd of 11 Medical Distribution companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | $1.6B | 3.20% |
| FY2024 | $1.5B | (12.31%) |
| FY2023 | $1.7B | 3.96% |
| FY2022 | $1.7B | 7.89% |
| FY2021 | $1.5B | — |
| FY2020 | −$3.4B | — |
| FY2019 | $854.1M | (47.14%) |
| FY2018 | $1.6B | 343.34% |
| FY2017 | $364.5M | (74.47%) |
| FY2016 | $1.4B | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Jun 2026 | $776.7M | (52.34%) |
| Mar 2026 | $1.6B | 187.84% |
| Dec 2025 | $566.1M | — |
| Sep 2025 | −$333.1M | — |
| 42 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| MCK McKesson Corporation compare | $5.3B |
| COR Cencora, Inc. | $2.6B |
| CAH Cardinal Health, Inc. compare | $1.7B |
| HSIC Henry Schein, Inc. compare | $426.0M |
| AHG Akso Health Group Sponsored ADR compare | $15.6M |
| HKPD Cellyan Biotechnology Co., Ltd compare | −$180.4K |
| COSM Cosmos Health Inc. compare | −$24.4M |
| FOCL FocalTherics compare | −$39.0M |
| ACH Accendra Health, Inc. compare | −$302.1M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on COR
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement